Two stocks in Healthcare
Johnson & Johnson vs Stryker: profit, growth, debt and price compared
Johnson & Johnson is stronger on 4 of 7 figures: profit margin, debt, dividend and price trend. Stryker is stronger on 2: sales growth and price for its expected profit.
Save both stocks to your watchlist and revisit their latest fundamentals.
| Johnson & JohnsonJNJ | StrykerSYK | |
|---|---|---|
| Net margin | Stronger: 16.2% | 13.8% |
| Revenue growth, past year | +5.86% | Stronger: +7.64% |
| Debt to equity | Stronger: 54.8% | 65.8% |
| Forward P/E | 23.5× | Stronger: 19.5× |
| Dividend yield | Stronger: 1.94% | 1.11% |
| Analysts | Buy · 22 | Buy · 27 |
| From its 200-day average | Stronger: +10.2% | −0.2% |
Share price over the past year
- Johnson & Johnson+36.3%
- Stryker−11.5%
18 Nov 202518 Nov 2026
Johnson & Johnson or Stryker: which is stronger?
- JNJ
Which is more profitable?
Johnson & Johnson keeps more of each sale as profit: 16.2% against 13.8%.
- SYK
Which is growing its sales faster?
Stryker is growing its sales faster: +7.64% over the past year, against +5.86%.
- JNJ
Which has borrowed less?
Johnson & Johnson has borrowed less: its debt is 54.8% of what its shareholders own, against 65.8% for Stryker.
- SYK
Which costs less for the profit it is expected to make?
Stryker costs less for the profit it is expected to make: 19.5× its forward earnings, against 23.5×.
- JNJ
Which pays more in dividends?
Johnson & Johnson pays more back in dividends for what a share costs: 1.94% a year, against 1.11%.
Which do analysts rate higher?
Analysts rate both the same: Buy.
- JNJ
Which is in the stronger price trend?
Johnson & Johnson's price is in the stronger trend: 10.2% above its 200-day average, against 0.2% below.
What each company does
JNJJohnson & Johnson
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide.
Reports results on 26 January 2027
SYKStryker
Stryker Corporation operates as a medical technology company in the United States and internationally.
Reports results on 28 January 2027
This comparison is just the starting point.
Discover opportunities, understand companies and compare investments in one place. See how StratDeck works
Keep researching
Where next
More comparisons
Free email
Up to speed in minutes, four times a week
Every Monday, know what moved AI stocks and what to watch next. Every Wednesday and Friday, find a stock worth a look and learn its story. Every Sunday, catch up on the market's week in two minutes.
Early access
Become a StratDeck founding user
Use StratDeck, tell us what's missing, and help decide what we build next.
100 founding places. Founding users get their first month free, then half price for life: £2.99 a month or £30 a year.